Summary Respiratory failure is an important terminal event in muscular dystrophy, but increasingly is effectively treated by non-invasive ventilation. This study was designed to assess mortality statistics in this patient group in order to get an indication of future demand.
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Mortality data for all deaths from muscular dystrophy registered by death certification in England and Wales between 1993 and 1999 were analysed.
In total, 817 deaths from muscular dystrophy were registered between 1993 and 1999. Annual number of deaths was unchanged over this period. Median age at death (interquartile range) for all cause muscular dystrophy increased from 20 (17-42.5) years in 1993, to 26 (17.5-63) years in 1999. Respiratory failure was the primary or contributory cause of death in 82% of cases. Two thirds of these deaths were during acute infection.
We can expect 100 patients with muscular dystrophy to develop respiratory failure in England and Wales each year, so non-invasive ventilation services probably need to be able to provide for 0.2 new patients per 100,000 population annually. Respiratory services also need to provide adequate monitoring and early treatment of infection in these patients. & 2005 Elsevier Ltd. All rights reserved.
Introduction
Respiratory failure, often exacerbated by respiratory infection, is an important cause of death in patients with muscular dystrophy. Since the early 1990s there has been a significant rise in the use of non-invasive ventilation (NIV) in this population, as it has become widely accepted as an effective means of managing respiratory failure. NIV has subsequently resulted in substantial improvements in survival in patients with slowly progressive muscular dystrophy. [1] [2] [3] Even in more rapidly progressive conditions such as Duchenne muscular dystrophy (DMD), NIV has been shown to prolong life by several years. 4 As a consequence, the number of patients with muscular dystrophy using NIV at home is steadily increasing. 5, 6 Since respiratory decompensation often occurs at the crucial time when patients are in the process of moving from paediatric to adult services, patients with muscular dystrophy are increasingly being referred to adult respiratory services for respiratory support and consideration of NIV.
In order to provide an adequate service for patients with muscular dystrophy, we need some indication of their future needs and the likely impact on respiratory services, and in particular NIV services, by this population. However, there is very little epidemiological data in the current literature on which to base any assessment of service requirements. The aim of this study is to collect detailed information on the pattern of number of deaths and age at death over time and on cause of death. We have therefore examined mortality statistics for all causes of muscular dystrophy in England and Wales over a 7-year period. This information can then be used to estimate future demand for respiratory services in this population.
Methods
The time trend in age at death and the effects of diagnostic category of muscular dystrophy and gender have been examined. We have also looked for any geographical variation in age at death that might reflect the presence of specialist clinics for the provision of NIV, and have examined the effects of social class as a possible marker of access to and uptake of NIV services.
Data collection
Mortality data for all deaths with muscular dystrophy mentioned on the death certificate were obtained from the National Statistics Office for the period 1993-1999. The data included the underlying cause of death, age at death, place of death, gender, regional health authority of usual residence, and occupational social class.
Underlying cause of death has been documented as text as supplied on the death certificate under Sections 1a, 1b, and 1c and classified as respiratory, cardiac, cardio-respiratory, muscular dystrophy or other. Age at death was recorded as age in years at the last birthday. Five diagnostic categories of muscular dystrophy were identified for the purpose of analysis-DMD, muscular dystrophy (unspecified), Beckers muscular dystrophy (BMD), limb girdle or facioscapulohumoral muscular dystrophy (LG/FSH), congenital muscular dystrophy and other muscular dystrophy (oropharyngeal, neuroaxonal, pseudohypertrophic, Emery Dreifess, Barths type, myotonic, scapuloperoneal, familial, merosine positive, spinal, ischemic, autosomal recessive).
Coding for regional health authorities corresponds to their reorganisation in 1996. Social class included an occupational code for the deceased if aged over 16 or the mother's occupation if under 16, and, respectively, for the spouse or father. Categories are professional and intermediate, skilled non-manual, skilled manual, semi-skilled, unskilled, and other/unknown. For the purpose of analysis the higher occupational social class was used.
Statistical analysis
The data was analysed in terms of median age at death by calendar year in relation to diagnostic category of muscular dystrophy and gender. Descriptive analyses were carried out using Microsoft Excel.
The independent effects of gender, diagnosis, social class, and health authority region of usual residence on the odds of death above the median age for the year of death were estimated by multiple logistic regression (effects were examined in the three most common diagnostic categories) [SPSS version 10] .
Results
A total of 817 people (677 males) were registered as having died from muscular dystrophy in England and Wales between 1993 and 1999. Table 1 shows number of deaths each year by diagnostic category and gender.
Median age (interquartile range) at death for all cause muscular dystrophy increased significantly from 20 (17-42.5) years in 1993 to 26 (17.5-63) years in 1999 (P ¼ 0:042) (Fig. 1) . The trend for median age at death over time for the three main diagnostic categories, DMD, muscular dystrophy (unspecified) and BMD, is shown in Fig. 2 . Median age at death for DMD did not change over the 7-year period (18 years in 1993 and 18.5 years in 1999), but the interquartile range widened (16-20 years in 1993 and 16-22.25 years in 1999).
Odds of death above median age were significantly higher in women than in men and this trend persisted when X-linked causes for muscular dystrophy were excluded from the analysis OR 6.6 (95% CI 2.8-15.2). The mutually adjusted odds ratios for these effects, after excluding X-linked causes, are shown in Table 2 .
There was no significant regional variation in odds of death above median age for all cause muscular dystrophy or on subgroup analysis. The odds of death above median age were unrelated to occupational social class.
Analysis of cause of death (Fig. 3) confirms that the majority were due to respiratory failure (59%), and a further 4% were due to cardio-respiratory failure. Deaths documented as 'muscular dystrophy' are most likely to be respiratory or cardiorespiratory. Therefore respiratory failure may contribute up to a total of 82% of deaths. Of the respiratory deaths, 327 (68%) were due to pneumonia/acute infection and 150 (31%) due to chronic respiratory failure. Other causes were documented as respiratory arrest (4) and pulmonary hypertension (1) .
ARTICLE IN PRESS
Analysis by diagnostic category shows confirmed respiratory deaths account for 56% of deaths in DMD, 65% in muscular dystrophy (unspecified), 35% in BMD, 56% in limb girdle muscular dystrophy, 67% in facioscapulohumoral muscular dystrophy, 67% in congenital muscular dystrophy and 53% in other muscular dystrophy.
Most deaths (59%) occurred in hospital and only 27% of deaths occurred at home.
Discussion
This study has found that the number of deaths each year from all causes of muscular dystrophy in England and Wales is unchanged between 1993 and 1999, but that median survival had increased to 26 years by 1999. The majority of deaths can be attributed to respiratory causes (82%), and 68% occur during acute infection. A high proportion of patients die in hospital.
Although our data may not comprise a complete record of all patients dying with muscular dystrophy due to misclassification or under-reporting on the death certificate, most patients with significant disease are likely to be included. Death certificate accuracy is high for rare fatal diseases such as muscular dystrophy, which are chronic and have high diagnostic accuracy. Furthermore, annual numbers of death recorded here are comparable to estimated rates based on expected incidence of muscular dystrophy in the UK. It is possible that Xlinked muscular dystrophy has been miscoded under muscular dystrophy (unspecified), but this does not appear to have had a significant influence on our results, since our analyses were similar when X-linked muscular dystrophy was excluded. We have no data on current survivors but it seems reasonable to assume that the affects of health authority region and social class are similar amongst survivors and those who have died. Women with muscular dystrophy live longer than men, even when X-linked muscular dystrophy is excluded from analysis. This was unexpected and a possible explanation for this is miscoding of X-linked muscular dystrophy under the more general muscular dystrophy codes. However, a true survival benefit for the female gender remains.
ARTICLE IN PRESS
There is now good evidence for the role of longterm NIV in the treatment of respiratory complications of muscular dystrophy, 3 and its use in this population has rapidly expanded over the past 15 years. Improvements in survival from DMD have been demonstrated at 2 years 7 and 5 years. 4 Rideau 8 has shown that without ventilatory support mean age of death in DMD was 19 years with 73% occurring as a consequence of respiratory failure. In UK specialist centres, NIV had improved mean survival to 25.3 years by the end of the 1990s. 9 Therefore the median age at death from DMD in this survey is lower than expected and did not increase over time. This suggests that the use of NIV in this population over the period examined may have been low compared with its use across Europe. The years examined in this study correspond to a time of growing acceptance for a role of NIV in muscular dystrophy in the UK, 10 and it is possible that after 1999 there have been improvements in age at death due to the use of NIV. It is now recommended that NIV should be considered in all patients with muscular dystrophy developing symptomatic hypercapnic respiratory failure. Although not all patients with muscular dystrophy will be suitable for NIV, an increasing proportion of them are being referred to respiratory services for assessment for this form of treatment as awareness of the benefits become more widely appreciated. 11 This may be reflected in our data by the widening of the interquartile range due to an increase in the upper quartile, indicating that a cohort of patients are living longer. This is likely to be due to the introduction of NIV.
From our data, we would expect up to 100 patients with muscular dystrophy to die from respiratory failure each year in the UK (population 60 million). This can be used as a guide to the likely demand on respiratory services from this population group. A recent European study estimates the prevalence of home mechanical ventilation users as 4.1 per 100,000 population in the UK 12 and 40% have neuromuscular disease, which includes muscular dystrophy as its largest group. A further 35% have thoracic cage abnormalities and 25% have lung and airways diseases. Although it is difficult to predict the proportion of patients for whom NIV would be suitable and indicated, our data suggests that NIV services in England and Wales probably need to be able to provide for a further 0.2 new patients with muscular dystrophy and respiratory failure per 100,000 population each year. Patients with muscular dystrophy often remain on NIV for longer than other patient groups 13 and this should be taken into account when planning service requirements. Currently, in the UK only a small percentage of patients with muscular dystrophy use NIV via a tracheostomy. 13 Regular monitoring of pulmonary function at home has been advocated for this group of patients, in order to identify early the need for cough assist and NIV. When patients are admitted, it is important that they are seen at a centre that can provide these facilities. However, previous surveys have suggested that 55% of home mechanical ventilation in neuromuscular disease is started non-electively during acute infections 14 and we found that two thirds of patients with muscular dystrophy die during acute respiratory infection. Firstly, this may represent a cohort of patients where NIV needs to be considered at an earlier stage. Secondly, the high proportion of patients developing infective respiratory complications as a terminal event must to taken into account when developing respiratory service provision for this population. The high proportion of deaths in hospital also raises the question of whether advance directives and palliative care facilities are being used optimally for these patients.
We were unable to demonstrate any effect of region of residence on age of death, which argues against any major inequity in provision or access to healthcare for muscular dystrophy patients within England and Wales. Similarly, there was no effect of occupational social class, suggesting that access to healthcare is not an important factor in survival. However, our database may be too small to detect such effects and it would be useful to reanalyse this once a larger database has been built up.
In conclusion, we have found that respiratory failure, often associated with acute respiratory infection, accounts for a significant number of deaths in patients with muscular dystrophy. Based on current mortality statistics, we suggest that the number of new patients with muscular dystrophy and respiratory failure that NIV services in England and Wales need to provide for each year is 0.2 per 100,000 population. In addition, respiratory services should have the resources for adequate monitoring and early treatment of infective exacerbations in this patient group.
